Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02996500 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

A Phase 2 study of Rheumatoid Arthritis, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
269
Enrollment target
20
Study locations

NCT02996500 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Pfizer. The registered enrollment target is 269 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02996500, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
269 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA who have had an inadequate response to MTX. PF-06650833 or matching placebo tablets will be administered orally QD under fasting conditions, and tofacitinib or matching tofacitinib placebo tablets will be administered orally BID for 12 weeks in a blinded fashion.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • DRUG Tofacitinib
  • DRUG PF-06650833

Study Locations (20)

Florida

  • Robert W. Levin, MD,PA - Clearwater
  • Millennium Research - Ormond Beach
  • Arthritis & Rheumatic Care Center - South Miami
  • Qps-Mra, Llc - South Miami

Texas

  • Accurate Clinical Management, LLC - Baytown
  • Accurate Clinical Management, LLC - Houston
  • Accurate Clinical Management, LLC - Houston
  • DM Clinical Research - Tomball

Arizona

  • Dory Hardy, PharmD - Tucson
  • Southern Arizona VA Health care System - Tucson

Republika Srpska

  • University Clinical Center Republic of Srpska - Banja Luka
  • Health Center Gradiska - Gradiška

Alabama

  • Clinical and Translational Research Center of Alabama, PC - Tuscaloosa

Georgia

  • Medical Associates of North Georgia - Canton

Kentucky

  • Graves Gilbert Clinic - Bowling Green

Louisiana

  • Arthritis and Diabetes Clinic, Inc. - Monroe

Trial Details

FieldValue
Enrollment Target 269 participants
Start Date 2016-11-10
Est. Completion 2018-08-15
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02996500

The ClinicalTrials.gov registry entry for NCT02996500 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02996500 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT02996500 about?

NCT02996500 is a clinical study titled "Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate". This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA who have had an inadequate response to MTX. PF-06650833 or matching pla...

What is the current status of trial NCT02996500?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 269 participants. The study started on 2016-11-10. Estimated completion is 2018-08-15.

What conditions does trial NCT02996500 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT02996500?

The interventions under investigation include: Placebo (DRUG), Tofacitinib (DRUG), PF-06650833 (DRUG).

Who is sponsoring clinical trial NCT02996500?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02996500 being conducted?

This trial has 20 study locations across Alabama, Arizona, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.